ABSTRACT Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand PARPi being investigated breast cancer subtypes. Currently, except for BRCA1/2 mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative cancer, there is inadequate identification of predictive biomarker...

This study aimed to determine the targeted efficacy of trastuzumab (Herceptin) on human epidermal growth factor receptor 2 (HER-2)-overexpressing metastatic esophageal cancer in an orthotopic mouse model. HER-2 overexpression and amplification of human esophageal primary and metastatic tumors were shown with HER-2-fluorescence in situ hybridization analysis and HER-2 immunostaining. Following o...

Antiangiogenic agents have been widely investigated in combination with standard chemotherapy or targeted cancer agents for better management of advanced cancers. Therapeutic agents that concurrently inhibit epidermal growth factor receptor and other angiokinases could be useful alternatives to combination therapies for epidermal growth factor receptor-dependent cancers. Here, we report the syn...

Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against ...

Esophageal cancer is a formidable challenge in the realm of treatment. Conventional methods such as surgery, chemotherapy, and immunotherapy have demonstrated limited success rates managing this disease. In response, targeted drug therapies emerged promising strategy to improve outcomes for patients. These aim disrupt specific pathways involved growth development esophageal cells. This review e...

Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). I...

BACKGROUND AND AIMS The human epidermal growth factor receptor type 2 (HER-2) seems to be sensitive to nitrogen mustard, because nitrogen mustard heavily alkylates on guanine. In this study, we examined the effects of nitrogen mustard on cell growth and expression of HER-2 proteins in cultured human breast cancer cells. METHOD The HER-2 protein levels on the cell surface of breast cancer cell...